SCHEMBL6131504

SCHEMBL6131504

Cc1cccc(-c2cccc(C(N)=O)c2N)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 0.48
PARP1 P09874 2/20 0.47
BCAT2 O15382 1/20 0.47
DHODH Q02127 1/20 0.47
CDC7 O00311 1/20 0.46
MAP4K4 O95819 2/20 0.45
ABL1 P00519 2/20 0.45
LCK P06239 2/20 0.45
FYN P06241 2/20 0.45
CSF1R P07333 2/20 0.45
FGFR1 P11362 2/20 0.45
KDR P35968 2/20 0.45
FLT3 P36888 2/20 0.45
TYRO3 Q06418 2/20 0.45
ROCK1 Q13464 2/20 0.45
NTRK3 Q16288 2/20 0.45
AURKB Q96GD4 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
DYRK3 O43781 1/20 0.45
ROCK2 O75116 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6667275 0.87 BCAT2 (0.65) TLR8PARP1BCAT2DHODHCDC7
SCHEMBL28282551 0.83 BCAT2 (0.50) PARP1BCAT2DHODHMAP4K4ABL1
SCHEMBL3784805 0.83 PARP1 (0.50) PARP1BCAT2MAP4K4ABL1LCK
SCHEMBL29723862 0.81 PARP1 (0.52) TLR8PARP1BCAT2DHODHCDC7
SCHEMBL3433069 0.81 BCAT2 (0.71) PARP1BCAT2HSD17B10IKBKBALDH1A1
SCHEMBL1512152 0.81 BCAT2 (0.59) PARP1BCAT2MAP4K4CSF1RFGFR1
SCHEMBL15515383 0.78 DHODH (0.51) TLR8PARP1BCAT2DHODHCDC7
SCHEMBL8814921 0.77 CDC7 (0.58) TLR8DHODHCDC7MAP4K4ROCK1
SCHEMBL3791160 0.76 BCAT2 (0.53) PARP1BCAT2MAP4K4ABL1LCK
SCHEMBL28399042 0.75 ADORA1 (0.53) MAP4K4ABL1LCKFYNCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878720-B2 VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2005-04-12 US disclosed
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2003-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, NR2E3 TLR8 46/4885PARP1 4072/4885BCAT2 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.